NCT02614027View on ClinicalTrials.gov

Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

CompletedOBSERVATIONAL
Enrollment

276

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

June 30, 2018

Conditions
LipodystrophyMetabolic Syndrome
Interventions
OTHER

Evaluation of metabolic syndrome

Evaluation and analytical determinations of the different components of the syndrome

OTHER

Evaluation of changes in fat by DXA while on current therapy

Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation

Trial Locations (1)

28034

Ramon y Cajal Hospital, Madrid

All Listed Sponsors
lead

Asociacion para el Estudio de las Enfermedades Infecciosas

NETWORK

NCT02614027 - Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances | Biotech Hunter | Biotech Hunter